Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APTAMER: ARV PK for Adherence Testing
NCT04302896Phase 1Completed
- Start
- Aug 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in human immunodeficiency virus type 1 infection (HIV-1) comparing DTG + FTC/TAF with DTG + TDF + 3TC (2 arms). Primary endpoints: Maximum concentration, Time to maximum concentration and 3 more. Started Aug 2020; status: completed.
02
Drugs
dolutegraviremtricitabinetenofovir alafenamidetenofovir disoproxil fumaratelamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04302896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04302896.